Use of menopausal hormone therapy (MHT, also known as hormone replacement therapy, HRT) is not associated with an increased risk of developing dementia, regardless of hormone type, dose, or duration, concludes a large UK study published by The BMJ today.

英国医学杂志今天发表的一项大型英国研究得出结论，无论激素类型、剂量或持续时间如何，使用更年期激素疗法(MHT，也称为激素替代疗法，HRT)与患痴呆症的风险增加无关。

Within the subgroup of women with a specific diagnosis for Alzheimer's disease, a slightly increased risk association was found with the use of oestrogen-progestogen treatments, but measurable only for long-term usage (5 years or more).

在被诊断为阿尔茨海默病的亚组妇女中，发现使用雌激素-孕激素治疗的风险略有增加，但仅在长期使用(5年或更长)时可测量。

The researchers say this study "brings clarity to previously inconsistent findings and should reassure women in need of menopausal hormonal therapy."

研究人员说，这项研究“澄清了以前不一致的发现，应该让需要更年期激素治疗的女性放心。”

MHT is used to relieve menopausal symptoms such as hot flushes, sleep disturbance, mood swings, memory loss, and depression. Treatments include tablets containing oestrogen only, or a combination of oestrogen and progestogen, as well as patches, gels, and creams.

MHT用于缓解更年期症状，如潮热、睡眠障碍、情绪波动、记忆力丧失和抑郁。治疗方法包括只含有雌激素的药片，或雌激素和孕激素的混合物，以及贴剂、凝胶和乳霜。

Some menopausal symptoms are similar to early signs of dementia. Laboratory studies and small trials have suggested a beneficial link between oestrogen and age-related brain decline. However, the largest trial of MHT, the Women's Health Initiative Memory Study, found an increased risk of developing dementia among users of oestrogen-progestogen treatments.

一些更年期症状类似于痴呆症的早期症状。实验室研究和小型试验表明，雌激素与年龄相关的大脑衰退之间存在有益的联系。然而，MHT最大的试验，妇女健康倡议记忆研究，发现雌激素-孕激素治疗的使用者患痴呆症的风险增加。

A recent large observational study in Finland flagged an increased risk of developing Alzheimer's disease among users of both oestrogen-only and oestrogen-progestogen treatments, but the study had some methodological weaknesses.

最近在芬兰进行的一项大型观察性研究表明，仅使用雌激素和雌激素-孕激素治疗的患者患阿尔茨海默病的风险增加，但该研究在方法上存在一些缺陷。